Physician profile
Jacob Mp Bloom
NPI 1770757130
$2,284.61
in general payments reported to CMS, 2019-2025
17 companies · $27.30 in 2025
The $27.30 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $102 · 2021: $94.93 · 2022: $276 · 2023: $238 · 2024: $369 · 2025: $27.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tepha INC | $768.32 | 2019 | |
| Motiva USA, LLC | $328.24 | 2024 | |
| Galderma Laboratories, L.P. | $231.05 | 2019-2024 | Dysport |
| Merz North America, INC. | $195.59 | 2019 | |
| Allergan, INC. | $170.35 | 2020-2022 | |
| Davol INC. | $154.78 | 2022 | |
| Abbvie INC. | $125.23 | 2019-2025 | Botox |
| Apyx Medical Corporation | $104.72 | 2019 | |
| Leo Pharma INC. | $40.53 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $39.79 | 2019-2024 | Exparel |
| Tela Bio, INC. | $27.66 | 2021 | |
| Genzyme Corporation | $23.43 | 2020 | |
| Axogen | $19.13 | 2020 | |
| Dermira, INC. | $16.21 | 2019 | |
| Boston Scientific Corporation | $15.10 | 2023 | Advantage System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $12.54 | 2020 | |
| Biom'Up Sa | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.